



# Molecular & Biomedical Pharmacology News

VOLUME 2, ISSUE 4

April 8, 2013

## Manuscripts

Sims JT, Ganguly SS, Bennett H, **Friend JW**, Tepe J, **Plattner R**. *Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF- $\kappa$ B and HSP27/p38/AKT pathways and by inhibiting ABCB1*. PLoS One. 2013; 8(1): Epub 2013 Jan 31

Papaya RS, **Shi T**, **Piasek MT**, Naga Prasad SV, Perez DM.  *$\alpha$ 1A-Adrenergic Receptors Regulate Cardiac Hypertrophy In Vivo Through IL-6 Secretion*. Mol Pharmacol. 2013 Feb 12.

Blomkalns AL, Gavrila D, Thomas M, Neltner BS, Blanco VM, Benjamin SB, McCormick ML, Stoll LL, Denning GM, Collins SP, Qin Z, Daugherty A, **Cassis LA**, Thompson RW, Weiss RM, Lindower PD, Pinney SM, Chatterjee T, Weintraub NL. *CD14 Directs adventitial macrophage precursor recruitment: role in early abdominal aortic aneurysm formation*. J Am Heart Assoc. 2013 Mar 8;2(2).

Chen X, Lu H, Rateri DL, **Cassis LA**, Daugherty A. *Conundrum of angiotensin II and TGF- $\beta$  interactions in aortic aneurysms*. Curr Opin Pharmacol. 2013 Mar 12.

Hoyt RE, Speakman RO, Brown DR, **Cassis LA**, Silcox DL, Anigbogu CN, Randall DC. *Chronic angiotensin-II treatment potentiates HR slowing in Sprague-Dawley rat during acute behavioral stress*. Auton Neurosci. 2013 Mar;174(1-2).

Dong C, Yuan T, **Wu Y**, Wang Y, Fan TW.M, Miriyala S, Lin Y, Yao J, Shi J, Kang T, Lorkiewicz P, St Clair D, Hung MC, Evers MB, Zhou BP. *Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer*. Cancer Cell. 2013 Mar 18 (Vol 23,3)

## CREATION OF THE INSTITUTE OF CLINICAL PHARMACOLOGY

The [Institute of Clinical Pharmacology](#) (ICP) was created to facilitate drug development at the University of Kentucky.



The Institute builds on programs of excellence in drug development within the nationally ranked College of Pharmacy and emerging programs in basic and clinical pharmacology within the Department of Molecular and Biomedical Pharmacology.

The ICP seeks to encourage clinical pharmacology and drug development research within the NIH funded University of Kentucky [Center for Clinical and Translational Science](#). We are currently seeking a director for the ICP who will provide leadership in Clinical Phase I and Phase II studies. The director will have the opportunity to recruit faculty and establish programs of excellence in Clinical Pharmacology as well as interact with emerging programs in drug discovery and clinical pharmacology in the College of Medicine and the College of Pharmacy. Details about the expectations and requirements for the ICP director are posted on the department website.

## Passing the Baton

We thank Olivier Thibault for serving for many years as the department's seminar director. Our new seminar director is Xuiwei Yang.



**New COM Website** was launched April 1, no fooling. The absence of your picture and profile is now evident to everyone. Fairly soon the COM will start pushing for compliance. Please go to [pharmacology.med.uky.edu/](http://pharmacology.med.uky.edu/) and help us make your presence known.

## Qing-Bai She awarded new RO1



The National Institutes of Health recently notified Dr. Qing-Bai She, assistant professor of Molecular and Biomedical Pharmacology, that he has been awarded a new RO1 CA175105-01 research grant. The \$1.2 million grant titled "Targeting Translation Dependence in Colorectal Cancer Progression" aims to lay the groundwork for

understanding the molecular mechanisms involved in the translational control of metastatic progression and treatment of colorectal cancer (CRC). This has great clinical relevance because a new therapy for metastatic CRC is urgently needed. We congratulate Dr. She for the recognition of his research in terms of NIH funding and support.